5d 1m 3m 1y 5y 10y
There are no Focus articles on ARUXF.
There are no Transcripts on ARUXF.
There are no News articles on ARUXF.
ARUXF vs. ETF Alternatives
Wednesday, Nov 242010, 8:26 AMThe FDA approves Axiron, Eli Lilly's (LLY) topical solution for testosterone replacement therapy in men. The U.S. testosterone market, estimated at $1B, is set to grow 20% annually. Acrux (ARUXF.PK), Lilly's Australian partner on the drug, rose 9.1% in Aussie trading. |Wednesday, Nov 242010, 8:26 AM| Comment!